Intest Res.  2022 Jan;20(1):1-2. 10.5217/ir.2021.00170.

Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

• Park J

• KMID: 2525067
• DOI: http://doi.org/10.5217/ir.2021.00170

Reference

1. Barberio B, Savarino EV, Card T, et al. Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intest Res. 2022; 21:114–123.

2. Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020; 69:274–282.

3. Song EM, Yang SK. Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res. 2021; Dec. 2. [Epub]. https://doi.org/10.5217/ir.2021.00104.

4. Huang W, Tang Y, Nong L, Sun Y. Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn’s disease: a meta-analysis of observational studies. J Crohns Colitis. 2015; 9:293–301.

5. Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn’s disease: is there a direct relationship? Therap Adv Gastroenterol. 2020; 13:1756284820931738.

6. Brouquet A, Maggiori L, Zerbib P, et al. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort. Ann Surg. 2018; 267:221–228.

7. Cohen BL, Fleshner P, Kane SV, et al. Anti-tumor necrosis factor therapy is not associated with post-operative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for postoperative infection I (PUCCINI). Gastroenterology. 2019; 156(6 Suppl 1):S–80.

8. Lightner AL, McKenna NP, Tse CS, Raffals LE, Loftus EV Jr, Mathis KL. Postoperative outcomes in vedolizumab-treated Crohn’s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther. 2018; 47:573–580.

9. Park KT, Sceats L, Dehghan M, et al. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther. 2018; 48:340–346.

10. Poylin VY, Serrato JC, Pastrana Del Valle J, Feuerstein JD. Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study. Intest Res. 2022; 21:72–77.